Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 17/20 | 0.54 |
| ▸ | HPGDS | O60760 | 2/20 | 0.49 |
| ▸ | CCNC | P24863 | 1/20 | 0.49 |
| ▸ | CDK8 | P49336 | 1/20 | 0.49 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.49 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.49 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.49 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.49 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.49 |
| ▸ | IRAK3 | Q9Y616 | 1/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.48 |
| ▸ | ITK | Q08881 | 3/20 | 0.47 |
| ▸ | IL2 | P60568 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 3/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.45 |
| ▸ | RAF1 | P04049 | 2/20 | 0.44 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27098632 | 0.97 | CRBN (0.54) | CRBNHPGDSCCNCCDK8IRAK1 | |
| SCHEMBL29547197 | 0.97 | CRBN (0.54) | CRBNHPGDSCCNCCDK8IRAK1 | |
| SCHEMBL31043971 | 0.92 | CRBN (0.56) | CRBNHPGDSIRAK1IRAK4IRAK3 | |
| SCHEMBL29927356 | 0.88 | CRBN (0.57) | CRBNHPGDSDDB1IKZF3 | |
| SCHEMBL29132159 | 0.88 | CRBN (0.57) | CRBNHPGDSDDB1IKZF3 | |
| SCHEMBL29919831 | 0.88 | CRBN (0.47) | CRBNIKZF3 | |
| SCHEMBL29919877 | 0.88 | CRBN (0.54) | CRBNIKZF3 | |
| SCHEMBL22291498 | 0.88 | CRBN (0.63) | CRBNHPGDSCCNCCDK8IRAK1 | |
| SCHEMBL29919906 | 0.88 | SIGMAR1 (0.45) | — | |
| SCHEMBL29919803 | 0.88 | SIGMAR1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590079-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-12391686-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20230077730-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2023-03-16 | — | — | US | disclosed |
| US-20220289711-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2022-09-15 | — | — | US | disclosed |
| CN-113874016-A | Compound and use thereof | 福宏治疗公司 | 2021-12-31 | — | — | CN | disclosed |
| EP-3917526-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| WO-2020160192-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12590079-B2 | Compounds and uses thereof | PSMB6, PSMC4, PSMB2 | CRBN 16/4885HPGDS 3685/4885CCNC 604/4885 |
| US-20230077730-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | CRBN 56/4885HPGDS 2505/4885CCNC 2362/4885 |
| US-12391686-B2 | Compounds and uses thereof | VHL, TFEB, BECN1 | CRBN 56/4885HPGDS 2505/4885CCNC 2362/4885 |
| US-20220289711-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | CRBN 179/4885HPGDS 3000/4885CCNC 3907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.